Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

Core Insights - Kymera Therapeutics, Inc. is set to host a video webcast on May 9, 2025, to report its first quarter 2025 financial results and introduce a new oral development candidate targeting autoimmune and rheumatic diseases [1] - The company will also review highlights and upcoming milestones in its immunology pipeline, which is considered industry-leading [1] Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation (TPD) to develop innovative medicines for significant health issues [3] - The company aims to create a pipeline of oral small molecule degraders that offer convenient and effective therapies for patients with immunological diseases [3] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [3] Communication and Information Availability - Investors and the public can access information about Kymera through its website, including corporate disclosures, investor presentations, and SEC filings [4] - The company encourages regular review of the information posted on its website and social media platforms [4]